Carcinoma of the breast with medullary-like features: Diagnostic challenges and relationship with BRCA1 and EZH2 functions

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 11, 2009, Pages 1822-1825

  Kleer, Celina G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ADULT; BREAST CARCINOMA; CASE REPORT; CONFERENCE PAPER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY;

BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, MEDULLARY; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 70449433173     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207(3):260-268. (Pubitemid 41556449)
2. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9(2):R24. (Pubitemid 350215163)
3. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66(9):4636-4644.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874. (Pubitemid 32878711)
5. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560-569. (Pubitemid 44200649)
6. Reis-Filho JS, Tutt NJ. Triple negative tumors: a critical review. Histopathology. 2008;52(1):108-118.
7. +) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64(3):830-835.
8. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22-34.
9. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-11218
10. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271. (Pubitemid 43117611)
11. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374. (Pubitemid 39100473)
12. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138-1145. (Pubitemid 28380718)
13. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175-5180. (Pubitemid 41003703)
14. Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin. Cancer Res. 2001;7(7):1937-1945.
15. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606-11611. (Pubitemid 37205983)
16. Kunju LP, Toy K, Thomas D, Ding Y, Kleer CG. Expression of the stem cell markers ALDH1 and EZH2 in triple negative invasive breast carcinomas. Poster presented at: 98th Annual Meeting of the United States and Canadian Academy of Pathology; March 7-13, 2009; Boston, MA.
17. Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2009;28(6):843-853.